• CFTRinh-172: Precision CFTR Inhibitor Workflows & Optimizati

  2026-08-04

  CFTRinh-172 stands out as a highly selective CFTR inhibitor, enabling rigorous control of cAMP-activated chloride channels for cystic fibrosis and secretory diarrhea research. This detailed guide integrates novel insights into CFTR trafficking, actionable protocol enhancements, and troubleshooting strategies for robust, reproducible epithelial assays.

• Metal-Ion-Chelating L-Phe Nanostructures Enhance ICB Immunot

  2026-08-04

  This study demonstrates that metal-ion-chelating L-phenylalanine nanostructures, in combination with short-term starvation, can remodel the immunosuppressive tumor microenvironment and potentiate immune checkpoint blockade in breast cancer models. By modulating dendritic cell ion channel activity and inflammasome signaling, this approach offers a mechanistically novel strategy to overcome resistance to immunotherapy.

• Applied Minocycline HCl Workflows for Neuroinflammation Rese

  2026-08-03

  Minocycline HCl bridges antimicrobial and neuroprotective research, uniquely enabling precise modulation of microglial activity in retinal and neurodegeneration studies. This article details actionable protocols, troubleshooting strategies, and innovative applications anchored in the latest evidence.

• Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Binding

  2026-08-03

  The referenced study identifies that truncated angiotensin peptides, including Angiotensin 1/2 (5-7), significantly enhance the binding of the SARS-CoV-2 spike protein to its alternative receptor AXL. These findings suggest new mechanisms for viral entry and highlight the importance of peptide fragments in both cardiovascular and infectious disease research.

• Axitinib (AG 013736): Rethinking Angiogenesis Inhibition in

  2026-08-02

  This thought-leadership article explores the mechanistic underpinnings, experimental validation, and translational significance of Axitinib (AG 013736) as a selective VEGFR tyrosine kinase inhibitor. Bridging recent insights from in vitro drug response metrics to advanced assay design, it provides strategic guidance for translational researchers seeking robust, reproducible data in cancer biology. The discussion integrates recent literature, highlights APExBIO’s product reliability, and outlines future opportunities for precision antiangiogenic research.

• OM-MSCs Mitigate Golgi Stress via PEDF-PI3K/Akt/mTOR After S

  2026-08-01

  This study uncovers how olfactory mucosa mesenchymal stem cells (OM-MSCs) attenuate Golgi apparatus stress responses after cerebral ischemia/reperfusion injury by activating the PEDF-PI3K/Akt/mTOR pathway. The findings offer mechanistic insight into neuroprotection, highlighting new avenues for targeting oxidative and Golgi stress in stroke models.

• Fumagillin Efficacy Against Azumiobodo hoyamushi in Aquacult

  2026-07-31

  This study systematically evaluated the in vitro and in vivo antiparasitic efficacy of 20 compounds, including Fumagillin, against Azumiobodo hoyamushi, the causative agent of soft tunic syndrome in Halocynthia roretzi. The findings clarify Fumagillin’s moderate potency and inform future strategies for disease control in aquaculture and beyond.

• Urolithin A for Mitochondrial Biogenesis Research: Workflows

  2026-07-31

  Urolithin A uniquely enables precise interrogation of mitophagy and mitochondrial gene regulation in cellular models, distinguishing itself as both a mechanistic probe and a tool for translational research. This guide details hands-on workflows, protocol pitfalls, and advanced applications to help researchers unlock new dimensions in mitochondrial quality control and antifibrotic studies.

• OATP1B3 Exhibits Enhanced N-Glycosylation Versus OATP1B1

  2026-07-30

  This study demonstrates that human OATP1B3, a hepatic transporter, is significantly more N-glycosylated than its homolog OATP1B1, particularly in extracellular loops 2 and 5. The findings highlight the essential role of N-glycosylation in surface expression and function, offering new insights for glycoprotein research and membrane protein labeling strategies.

• SB-3CT: Bridging Gelatinase Inhibition with Translational Im

  2026-07-30

  This thought-leadership article explores the mechanistic and translational significance of SB-3CT, a selective gelatinase inhibitor, in advancing tumor metastasis and neuroprotection research. By integrating mechanistic insights on MMP-2/9 targeting, referencing recent discoveries in ECM biology, and offering strategic guidance for experimental design, it positions SB-3CT as a cornerstone for impactful translational studies.

• Verapamil ((±)-Verapamil): Beyond Calcium Channels in Hypoxi

  2026-07-29

  Explore how Verapamil ((±)-Verapamil) from APExBIO uniquely advances hypoxia-inflammation research by targeting the ROS/TXNIP/NLRP3 axis—revealing implications for urothelial and cardiovascular assay design. Discover new protocol insights and strategic considerations in this in-depth analysis.

• A-769662: Precision AMPK Activation and Metabolic Pathway Co

  2026-07-29

  Explore how the potent AMPK activator A-769662 enables nuanced regulation of energy metabolism, autophagy, and proteasome function. This article delivers advanced insights and critical updates for assay design and metabolic research.

• EdU Imaging Kits (488): Setting New Standards in Scalable Ce

  2026-07-28

  Explore EdU Imaging Kits (488) for high-sensitivity cell proliferation analysis using 5-ethynyl-2'-deoxyuridine, with an in-depth look at scalability, workflow optimization, and insights from advanced biomanufacturing studies.

• PD-L1 and IL-6 Crosstalk in PSC Revealed by Spatial Proteomi

  2026-07-28

  This study applies spatial proteomics and cell-cell cross-talk analysis to uncover a direct interaction between PD-L1 and IL-6 signaling in human primary sclerosing cholangitis (PSC). The findings highlight a mechanistic link at the epithelial-immune interface, offering new perspectives for targeting inflammatory pathways in cholangiopathies.

• NBC19: Unlocking NLRP3 Inflammasome Inhibition for Translati

  2026-07-27

  This thought-leadership article explores NBC19, a nanomolar-potent NLRP3 inflammasome inhibitor from APExBIO, as a transformative tool for inflammation and sepsis research. Integrating mechanistic insights from recent discoveries on lactate-driven HMGB1 release with practical guidance for translational workflows, the piece offers researchers a roadmap for leveraging NBC19 to dissect cytokine signaling, model disease processes, and accelerate bench-to-bedside translation.

451 records 9/31 page Previous Next First page 上5页 678910 下5页 Last page